Quantcast

Italian lawmakers approve controversial stem cell therapy

By Agence France-Presse
Wednesday, May 22, 2013 12:32 EDT
google plus icon
Assistant Professor Stormy Chamberlain studies stem cells at the University of Connecticut on August 27, 2010. (AFP)
 
  • Print Friendly and PDF
  • Email this page

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

At one demonstration, protesters wore T-shirts with the slogan: “Yes to Stamina, Yes to Life”.

The association Stem Cell Research Italy has branded the new law as “unacceptable” saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.

US journal Nature said it was a “rogue” therapy.

Agence France-Presse
Agence France-Presse
AFP journalists cover wars, conflicts, politics, science, health, the environment, technology, fashion, entertainment, the offbeat, sports and a whole lot more in text, photographs, video, graphics and online.
 
 
 
 
By commenting, you agree to our terms of service
and to abide by our commenting policy.
 
Google+